新型口服抗凝剂与华法林用于房颤复律患者的比较 - Suppr | 超能文献

New oral anticoagulants versus Warfarin in patients undergoing cardioversion of atrial fibrillation.

作者信息

Andò Giuseppe, Trio Olimpia

机构信息

Department of Clinical and Experimental Medicine, University of Messina, Italy.

Department of Clinical and Experimental Medicine, University of Messina, Italy.

出版信息

Int J Cardiol. 2016 Dec 15;225:244-246. doi: 10.1016/j.ijcard.2016.09.126. Epub 2016 Oct 1.

DOI:10.1016/j.ijcard.2016.09.126

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

New oral anticoagulants versus Warfarin in patients undergoing cardioversion of atrial fibrillation.新型口服抗凝剂与华法林用于房颤复律患者的比较

Int J Cardiol. 2016 Dec 15;225:244-246. doi: 10.1016/j.ijcard.2016.09.126. Epub 2016 Oct 1.

2

Non-vitamin K antagonists oral anticoagulants are as safe and effective as warfarin for cardioversion of atrial fibrillation: A systematic review and meta-analysis.非维生素 K 拮抗剂口服抗凝药与华法林在心房颤动转复中同样安全有效：系统评价和荟萃分析。

Int J Cardiol. 2018 Oct 1;268:143-148. doi: 10.1016/j.ijcard.2018.04.034.

3

Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation).在心房颤动转复后应用阿哌沙班的疗效和安全性：来自 ARISTOTLE 试验（阿哌沙班用于减少心房颤动中的中风和其他血栓栓塞事件）的见解。

J Am Coll Cardiol. 2014 Mar 25;63(11):1082-7. doi: 10.1016/j.jacc.2013.09.062. Epub 2013 Nov 6.

4

[Termination of paroxysm of atrial fibrillation conversion using oral propafenone after unsuccessful electrical cardioversion].[电复律失败后口服普罗帕酮终止心房颤动发作的转复情况]

Kardiologiia. 2012;52(4):95-6.

5

[Anticoagulation in atrial fibrillation before cardioversion].[房颤复律前的抗凝治疗]

Dtsch Med Wochenschr. 1999 Apr 1;124(13):407.

6

Real-life experience with non-vitamin K antagonist oral anticoagulants versus warfarin in patients undergoing elective cardioversion of atrial fibrillation.非维生素 K 拮抗剂口服抗凝剂与华法林在择期行心房颤动转复患者中的真实世界经验。

Ann Noninvasive Electrocardiol. 2020 Sep;25(5):e12766. doi: 10.1111/anec.12766. Epub 2020 Apr 29.

7

Spontaneous conversion in patients with non-valvular atrial fibrillation planned for electrical cardioversion: A subanalysis of the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion Of Atrial Fibrillation (ENSURE-AF) trial.计划进行电复律的非瓣膜性心房颤动患者的自发转复：心房颤动电复律患者中依度沙班与华法林对比研究（ENSURE-AF）试验的亚组分析

Am Heart J. 2019 Mar;209:131-135. doi: 10.1016/j.ahj.2018.10.008. Epub 2018 Nov 22.

8

[Cardioversion in atrial fibrillation].

Rev Prat. 2002 Jun 15;52(12):1313-6.

9

Evaluating cardioversion outcomes for atrial fibrillation on novel oral anticoagulants versus warfarin: experience at a tertiary referral centre.评估新型口服抗凝药与华法林用于心房颤动复律的效果：一家三级转诊中心的经验

Ir J Med Sci. 2017 Aug;186(3):615-620. doi: 10.1007/s11845-017-1582-3. Epub 2017 Feb 24.

10

Rivaroxaban vs. Warfarin for Anticoagulation in Patients with Atrial Fibrillation Undergoing Ablation and Cardioversion.利伐沙班与华法林用于接受消融和心脏复律的房颤患者抗凝治疗的比较

Am Fam Physician. 2016 Oct 1;94(7):Online.

引用本文的文献

1

How to Optimize Cardioversion of Atrial Fibrillation.如何优化心房颤动的心脏复律

J Clin Med. 2022 Jun 12;11(12):3372. doi: 10.3390/jcm11123372.

2

Management of Direct Oral Anticoagulants in Patients with Atrial Fibrillation Undergoing Cardioversion.心房颤动患者电复律时直接口服抗凝剂的管理。

Medicina (Kaunas). 2019 Sep 30;55(10):660. doi: 10.3390/medicina55100660.